imported>KansasC785 at 14:59, 10 July 2021

2021-07-10T14:59:13Z

New page

{{Short description|Generic Pharmaceutical Manufacturing Company}}
{{Infobox company
|name = Panacea Biotec
|logo =
|type = [[Public company|Public]]
| founded = 1984
|location = [[New Delhi]], [[India]]
|key_people = Soshil Kumar (Executive [[Chairman]] of the Board), Dr. Rajesh Jain ([[Managing Director]]), Sandeep Jain (Joint [[Managing Director]])
|industry = [[Pharmaceutical industry]]
|products = [[Pharmaceutical]]s, [[generic drug]]s, [[vaccine]]
|homepage = [http://www.panaceabiotec.com www.panaceabiotec.com]
}}

'''Panacea Biotec''' is a global [[Generic drug|generic]] and [[Pharmaceutical industry|specialty pharmaceutical]] and [[vaccine]] maker registered in [[India]] with principal offices in New [[Delhi]], [[Mumbai]], and Lalru (near [[Chandigarh]], India). Panacea Drugs Pvt. Ltd. was set up in the year 1984 and got listed in 1995 as Panacea Biotec Ltd. The company has grown organically to become one of the largest vaccine manufacturers in India. It has strong roots in research, development, manufacturing and marketing of pharmaceutical formulations, [[vaccine]]s, biosimilars, and natural products.<ref>{{cite news|url=http://www.iht.com/articles/2005/08/17/bloomberg/sxbio.php|title=New vaccines to lift sales at Panacea Biotec|date=18 August 2005|work=[[International Herald Tribune]]|accessdate=2009-03-05}}</ref> [[Russian Direct Investment Fund|Russian Direct Investment Fund (RDIF)]] collaborated with Panacea Biotec to produce [[Sputnik V COVID-19 vaccine|'Sputnik V' Covid-19 vaccine]] in [[India]].<ref>{{Cite news|date=May 25, 2021|title=RDIF, Panacea Biotec start Sputnik V Covid vaccine production in India|work=[[India Today]]|url=https://www.indiatoday.in/coronavirus-outbreak/story/rdif-panacea-biotec-start-sputnik-v-covid-vaccine-production-starts-in-india-1806528-2021-05-25|access-date=May 28, 2021}}</ref>

It is one of the three largest biotechnology companies in India.<ref>[http://www.expresspharmaonline.com/20111215/bioph2011special01.shtml Risky Business], Express Pharma, December 2, 2011</ref> The company develops and produces medicines for a wide range of medical disciplines, including [[oncology]], [[Organ transplantation|organ transplant]], [[immunology]] and [[pain management]], [[gastroenterology]], [[vaccine]]s, and diabetology/[[endocrinology]].

In August 2011, several of its [[hepatitis]] vaccines were removed from the list of prequalified vaccines by the [[World Health Organization]]<ref>[http://timesofindia.indiatimes.com/business/india-business/Bharat-Biotech-gets-WHO-blow-over-Hep-B-vaccine/articleshow/11114310.cms "Bharat Biotech gets WHO blow over Hep-B vaccine"], The Times of India, December 15, 2011</ref> because of quality management issues, but the issues were resolved by early 2012.<ref>[http://www.equitybulls.com/admin/news2006/news_det.asp?id=99119 equitybulls.com]</ref> Its leading product, EasyFive-TT, regained WHO PQ in September 2013.<ref>{{cite web |title=Easyfive TT vaccine to be back in WHO list: Panacea Biotec |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/easyfive-tt-vaccine-to-be-back-in-who-list-panacea-biotec/articleshow/22760191.cms?from=mdr |website=The Economic Times |accessdate=9 July 2020 |date=19 September 2013}}</ref>

==History==
Panacea Biotec is one of the largest vaccine manufacturers and pharmaceutical companies in India. Panacea Biotec is focused on research in Vaccines, Pharmaceuticals, Biosimilars, and Nutraceuticals.

=== Transplant ===
Panacea Biotec has many drugs for kidney and liver transplant such as [[Tacrolimus]] (marketed as PanGraf), [[Mycophenolic acid]] (Mycept), [[Mycophenolate|mycophenolate sodium]] (Mycept S), etc. It also markets generic forms of Tacrolimus<ref>{{Cite web|url=https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=090802|title=Panacea Biotec markets Tacrolimus for Organ Transplant in the United States|last=|first=|date=|website=|access-date=}}</ref> in the [[United States]],<ref>{{Cite web|url=https://www.accessdata.fda.gov/scripts/Cder/ob/results_product.cfm?Appl_Type=A&Appl_No=090802|title=Orange Book: Approved Drugs|last=|first=|date=|website=|access-date=January 1, 2019}}</ref> [[Germany]], among many other developing countries.

===Nephrology===
Panacea Biotec has a focused presence in nephrology therapy in the highly specialized organ transplantation and dialysis management segments. It offers a range of pre-transplant and post-transplant therapies that include drugs such as [[lanthanum carbonate]], [[sevelamer]], and [[valganciclovir]] in conventional and novel [[drug delivery]] systems.

===Gastroenterology and orthopaedic===
Panacea Biotec has many products for treatment of [[arthritis]], [[Hemorrhoid|haemorrhoids]], acid reflux, and other gastrointestinal problems. Its most prominent product is Sitcom, a [[Euphorbia prostrata|euphorbia prostata extract]] that helps different grades of [[Hemorrhoid|haemorrhoids]]. It also markets a once-a-day combination of regular and controlled-release [[Aceclofenac]] (generic to Clanza CR) under the brand name Willgo CR.

===Oncology===
Panacea Biotec has many brands marketed in India for the 'affordable' treatment for cancer, viz, [[breast cancer]], [[brain tumor]], ovarian cancer, [[pancreatic cancer]], prostate cancer and colorectal cancer. One of its most prominent brand in this segment is, PacliAll, which is a generic version of [[Protein-bound paclitaxel|Abraxane Protein-bound paclitaxel]]. The company has plans to market the product in the US as per the patent settlement.<ref>{{Cite web|url=https://www.livemint.com/Companies/RPXLW71KTB5o3rVTEsHvCP/Panacea-settles-patent-dispute-with-USbased-Celgene-Corp.html|title=Panacea Biotec settles patent dispute with US-based Celgene|last=|first=|date=|website=|access-date=}}</ref>

=== Diabetes ===
The company has extensively focused on its diabetic portfolio with formulations such as [[gliclazide]], [[metformin]], and [[glimepiride]] that are marketed in India and other developing markets under the brand names Glizid, Glizid M, Glizid MR, Betaglim, and Metlong. It is one of the largest diabetic companies in its represented market.

== Vaccines ==
Panacea Biotec markets many generic and novel vaccines in India and many global markets. Some of its vaccines are Pre-qualified by the [[World Health Organization|WHO]].

''The listing below is for named vaccines; Panacea Biotec produces many vaccines which do not bear trade names.''

* [[Polio vaccine]]s
* [[Hib vaccine|Haemophilus influenzae type b vaccines]]
* [[DPT vaccine|Diphtheria, tetanus and polio combined vaccines]]
* DPT, haemophilus combined vaccines
* DPT, polio combined vaccines
* DPT, haemophilus, polio combined vaccines
* DPT, haemophilus, polio, hepatitis B combined vaccines
* [[Dengue vaccine]]s
* [[Influenza vaccine]]s
* [[Tetanus vaccine]]s
* [[Pneumococcal vaccine]]

As of July 2020, the company is also developing a vaccine for [[Severe acute respiratory syndrome coronavirus 2|SARS-COV-2]] using a Whole inactivated Virus approach. It also got a huge investment in April 2020 from a US based pharma firm.<ref>{{cite web |title=Panacea Biotec and Refana team up for Covid-19 vaccine |url=https://www.pharmaceutical-technology.com/news/panacea-biotec-refana-vaccine/ |website=Pharmaceutical Technology |accessdate=9 July 2020 |date=10 June 2020}}</ref>

In May 2021, Panacea Biotec tie up with [[Russian Direct Investment Fund|Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund)]] to produce 100 million doses of [[Sputnik V COVID-19 vaccine]] annually in India.<ref>{{Cite news|date=April 5, 2021|title=India's Panacea Biotec to produce 100 mln Sputnik V doses annually -RDIF|work=[[Reuters]]|url=https://www.reuters.com/business/healthcare-pharmaceuticals/indias-panacea-biotec-produce-100-mln-sputnik-v-doses-annually-rdif-2021-04-05/|access-date=May 28, 2021}}</ref>

== Notable achievements ==

* In 1998, Panacea Biotec was awarded its first product patent for [https://patents.google.com/patent/US5716609A/en?assignee=panacea+biotec&oq=panacea+biotec Nimulid transgel].
*In 2005, Panacea Biotec was the first to launch a fully-liquid [[Pentavalent vaccine]] (DTwP-HepB-Hib), EasyFive in India and it was subsequently, pre-qualified by the [[World Health Organization|WHO]] for introduction in various [[Gavi, the Vaccine Alliance|GAVI]] countries.
*In 2006, collaboration with the Netherlands Vaccine Institute (the Nederlands Vaccin Instituut (NVI)) for manufacture and marketing of a finished inactivated polio Vaccine (IPV) and a number of IPV-based combination vaccines in India and across the globe
*In 2008, [[World Health Organization|WHO]] prequalification for fully liquid innovative combination [[pentavalent vaccine]], EasyFive against five deadly infectious diseases (DTwP+ Hep B+ Hib) of early childhood
* In 2011, Panacea Biotec was the first to launch PacliAll, the world's first generic to [[Protein-bound paclitaxel|Abraxane Protein-bound paclitaxel]] in India.
* In 2017, Panacea Biotec was the first to launch a fully-liquid Hexavalent vaccine (DTwP-HepB-Hib-IPV), EasySix in India.

== Hospital venture ==
Panacea Biotec sold its near-completed hospital in [[Delhi]] NCR to [[Narayana Hrudayalaya]] in April 2017<ref>{{Cite web|url=https://www.livemint.com/Companies/m8RpqX8Hk75FQ8Qd7HiCwL/Narayana-Hrudayalaya-to-buy-Panacea-Biotecs-NewRise-Healthc.html|title=Narayana Hrudayalaya to buy Panacea Biotec's NewRise Healthcare for Rs180 crore|last=|first=|date=|website=|access-date=}}</ref> for 180 crores; effectively, exiting the hospital business.

==References==
{{Reflist}}

== External links ==
*[https://www.panaceabiotec.com/ Panacea Biotec's official site]

{{Authority control}}

[[Category:Pharmaceutical companies of India]]

Panacea Biotec - Revision history

imported>KansasC785 at 14:59, 10 July 2021